AstraZeneca (AZN) Investor update summary
Event summary combining transcript, slides, and related documents.
Investor update summary
15 Jul, 2026Sustainability strategy and context
Sustainability is integrated into business strategy, focusing on climate action, health equity, and health system resilience, underpinned by science, innovation, and ethical governance.
AI and digital tools accelerate drug discovery, improve operational efficiency, and support earlier diagnosis and targeted care.
Business growth and decarbonization have progressed together, with an 88% reduction in Scope 1 and 2 emissions since 2015 and a target of 98% by 2026.
Over 80% of supplier spend is with companies committed to science-based targets, and 81% of the global fleet is now electric.
Commitment to responsible, ethical business practices and robust governance, guided by company values and executive leadership.
Climate and nature action
Scope 3 emissions target updated to a 35% reduction by 2030 versus 2019, aligned with business growth and a net zero goal by 2045.
$500 million invested in next-generation inhaler propellants with near zero global warming potential, already approved and in use in the UK and Europe.
Supplier engagement includes contract requirements, renewable energy initiatives, and joint decarbonization actions.
AZ Forest target adjusted to 100 million trees by 2030, focusing on high-quality projects and aiming for 50% waste circularity.
Nature strategy includes eliminating horseshoe crab blood in testing and promoting sustainable sourcing.
Health equity and access
Over 40% of genomic data now comes from underrepresented populations, supporting broader patient benefit.
Health equity programs have positively impacted 156 million people from underserved communities since 2024.
Aim to reach 1 billion people through medicines, clinical trials, education, and screening by 2030, with 400 million from underserved groups.
More than 60 partnerships with NGOs through the Young Health Programme.
Programs like Healthy Heart Africa and partnerships for newborn screening expand early detection and intervention.
Latest events from AstraZeneca
- 2024 revenue up 21% to $54.1bn, core EPS up 19%, with strong growth and robust 2025 outlook.AZN
Q4 20249 Jul 2026 - Q1 2025 revenue up 10% at CER, Core EPS up 21%, guidance reaffirmed.AZN
Q1 20259 Jul 2026 - Q1 2026 saw 13% revenue growth, strong Oncology and Rare Disease gains, and reaffirmed guidance.AZN
Q1 20268 Jul 2026 - Double-digit revenue and EPS growth in H1 2025, led by Oncology and strong pipeline progress.AZN
Q2 20251 Jul 2026 - Elecoglipron's Phase IIb results support global phase III trials and ambitious revenue growth.AZN
Investor update9 Jun 2026 - EMERALD-3 delivers strong PFS gains; pipeline and ADCs drive oncology growth and innovation.AZN
Investor update3 Jun 2026 - Revenue up 8% to $58.7bn, Core EPS up 11%, with strong pipeline and global growth outlook.AZN
Q4 202513 Apr 2026 - 18% H1 2024 revenue growth drives upgraded mid-teens % guidance and broad-based segment gains.AZN
Q2 20243 Feb 2026 - NIAGARA sets a new standard in bladder cancer as ADC and IO innovation drive future growth.AZN
European Society for Medical Oncology Congress (ESMO) 202420 Jan 2026